DIASORIN S.P.A., THE ORDINARY SHAREHOLDERS’ MEETING AUTHORIZED THE BOARD OF DIRECTORS TO THE PURCHASE AND DISPOSITION OF TREASURY SHARES

Saluggia, October 4th, 2011 – The Ordinary Shareholders’ Meeting came to order today in Milano under the chairmanship of Gustavo Denegri, with shareholders representing 72.604% of the Company’s share capital in attendance.

The Shareholders’ Meeting resolved to authorize, pursuant to and for the purposes of Article 2357 of the Italian Civil Code, the purchase, in one or more installments and for a period of 18 months from the date of this resolution, Company common shares up to a number that, counting any treasury shares held by the Company from time to time, may not exceed in the aggregate the ceiling set forth in the applicable regulations in effect at any given time, empowering the Board of Directors, prior to the start of each buying program, to determine the number of shares that may be purchased in pursuit of the authorized purposes at a price that shall not be higher than the price of the latest independent transaction or the highest current independent bid price in the trading system in which the purchase is being executed, whichever is greater, it being understood that the price per share may never be lower by more than 20% or higher by more than 15% compared with the simple average of the closing prices of the DiaSorin Spa stock in the 10 stock market trading days preceding each individual buy transaction.

The same Shareholders decided also to convey to the Board of Directors and, acting severally on the Board’s behalf, its Chairman and the Company’s Chief Executive Officer, the authority required under article 2357 ter of the Italian Civil Code to dispose of, at any time, in whole or in part, in one or more transactions, of the treasury shares acquired in
accordance with this resolution or otherwise held by the Company, by selling them on or off the stock exchange, without any time limit.

For any further detail please consult the Information Memorandum of the Board made available according to the terms and conditions of the Issuers’ Regulation Consob.

About DiaSorin
DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.DiaSorin.com

Contacts:

**Investor Relations DiaSorin**
Laura Villa  
DiaSorin S.p.A.  
laura.villa@DiaSorin.it  
+39 0161487532  
+39 348 15 11 542

**Press Office**
Carolina Mailander  
c.mailander@mailander.it  
+39 335 655 56 51  
Bruno Caprioli  
caprioli@mailander.it  
+39 335 590 14 02